Michael Barbella, Managing Editor10.29.22
A handful of firsts drove ODT website traffic this week.
BONESUPPORT and Life Spine both marked the clinical debuts of a bone graft and expandable spacer system, respectively, while DePuy Synthes won FDA approval for its adolescent spinal deformity treatment and THINK Surgical received a $100 million investment from a new investor (KDB Investment Global Healthcare of Korea).
Leading the charge, however, was Red Point Medical's improved design of its titanium Better Bunion custom Lapidus guides for reconstructive bunion surgeries. As CEO Ben Coburn explained, “We continue to enhance the RPM-3D proprietary, AI-enabled software called RedPoint Intelligence. Our advancements on the software front have significantly improved our processing techniques, and as a result we have achieved a 63% reduction in our guide development time. With our continued efforts to enhance our patient-specific guide design through intelligent software improvements, we are now capable of completing one custom guide every 15 minutes per technician level operator."
DePuy Synthes also racked up pageviews with the FDA 510(k) clearance of its ALTALYNE Ultra Alignment System for adolescent spinal deformities such as scoliosis. Designed to address unmet clinical needs related to intraoperative rod flattening, the ALTALYNE Ultra Alignment System offers a 5.5 millimeter profile with 36 percent greater resistance to rod flattening than a standard 6.0-millimeter Cobalt Chromium rod.
BONESUPPORT's and Life Spine's clinical milestones garnered cybervisitor interest as well. Doctors used BONESUPPORT's antibiotic-eluting bone graft CERAMENT G (Gentamicin) for the first time in U.S. patients suffering from a bone infection (osteomyelitis) caused by fractures induced by trauma. Spine surgeons, meanwhile, implanted Life Spine's ProLift Micro Endoscopic Expandable Spacer System for the first time. ProLift Micro supports endoscopic, TLIF/PLIF, MIS, and open procedures. It’s offered in an 8mm width, expands in-situ to 13mm, and can be deployed through a micro invasive cannula with endoscopic visualization.
BONESUPPORT and Life Spine both marked the clinical debuts of a bone graft and expandable spacer system, respectively, while DePuy Synthes won FDA approval for its adolescent spinal deformity treatment and THINK Surgical received a $100 million investment from a new investor (KDB Investment Global Healthcare of Korea).
Leading the charge, however, was Red Point Medical's improved design of its titanium Better Bunion custom Lapidus guides for reconstructive bunion surgeries. As CEO Ben Coburn explained, “We continue to enhance the RPM-3D proprietary, AI-enabled software called RedPoint Intelligence. Our advancements on the software front have significantly improved our processing techniques, and as a result we have achieved a 63% reduction in our guide development time. With our continued efforts to enhance our patient-specific guide design through intelligent software improvements, we are now capable of completing one custom guide every 15 minutes per technician level operator."
DePuy Synthes also racked up pageviews with the FDA 510(k) clearance of its ALTALYNE Ultra Alignment System for adolescent spinal deformities such as scoliosis. Designed to address unmet clinical needs related to intraoperative rod flattening, the ALTALYNE Ultra Alignment System offers a 5.5 millimeter profile with 36 percent greater resistance to rod flattening than a standard 6.0-millimeter Cobalt Chromium rod.
BONESUPPORT's and Life Spine's clinical milestones garnered cybervisitor interest as well. Doctors used BONESUPPORT's antibiotic-eluting bone graft CERAMENT G (Gentamicin) for the first time in U.S. patients suffering from a bone infection (osteomyelitis) caused by fractures induced by trauma. Spine surgeons, meanwhile, implanted Life Spine's ProLift Micro Endoscopic Expandable Spacer System for the first time. ProLift Micro supports endoscopic, TLIF/PLIF, MIS, and open procedures. It’s offered in an 8mm width, expands in-situ to 13mm, and can be deployed through a micro invasive cannula with endoscopic visualization.